Having demonstrated a valuable therapeutic strategy involving STAT3 inhibition in NPC, this work should provide impetus for the clinical evaluation of biological modifiers that may enhance cisplatin treatment and radiotherapy and potentially reduce undesirable side effects associated with currently available treatment strategies. Here, STAT3 is linked to nasopharyngeal carcinoma.